StreetInsider.com News Articles

Brad Hively to exit Starling Oncology board at 2027 annual meeting

Wed, 02 Sep 2026 06:08:55 -0400

Brad Hively has informed Starling Oncology, Inc. (NASDAQ: STLN) of his decision not to stand for re-election to the company's board of directors at its 2027 annual meeting of stockholders, according to a press release statement.

Hively notified the company on September 1, 2026. He is expected to continue serving as a director until the annual meeting, but has immediately stepped down from his role as Vice Chairman of the Board and as a member of the Compliance Committee and any other board committees.

The company stated that Hively's decision is not the result of any disagreement with the company on any

Brad Hively to exit Starling Oncology board at 2027 annual meeting

Wed, 02 Sep 2026 06:08:55 -0400

The company stated that Hively's decision is not the result of any disagreement with the company on any

Starling Oncology to Participate in Wells Fargo Healthcare Conference

Mon, 24 Aug 2026 09:00:00 -0400

CERRITOS, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Starling Oncology™, Inc. (NASDAQ: STLN), (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today announced that Dr. Daniel Virnich, Chief Executive Officer, and Rob Carter, Chief Financial Officer, will participate in the Wells Fargo Healthcare Conference, being held in Boston on Tuesday, September 8, 2026, including a fireside chat from 4:30–5:05 p.m. ET.

A webcast link of the presentation will be accessible through the Investor Relations section of the Company’s website at https://investors.starlingoncology.com/.

About Starling Oncology, Inc.

Starling Oncology to Participate in Wells Fargo Healthcare Conference

Mon, 24 Aug 2026 09:00:00 -0400

A webcast link of the presentation will be accessible through the Investor Relations section of the Company’s website at https://investors.starlingoncology.com/.

About Starling Oncology, Inc.

Starling Oncology to Participate in Wells Fargo Healthcare Conference

Mon, 24 Aug 2026 09:00:00 -0400

A webcast link of the presentation will be accessible through the Investor Relations section of the Company’s website at https://investors.starlingoncology.com/.

About Starling Oncology, Inc.

Starling Oncology to Participate in Wells Fargo Healthcare Conference

Mon, 24 Aug 2026 09:00:00 -0400

A webcast link of the presentation will be accessible through the Investor Relations section of the Company’s website at https://investors.starlingoncology.com/.

About Starling Oncology, Inc.

Form 8-K Starling Oncology, Inc. For: Aug 20

Fri, 21 Aug 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20260821/26962534.html

Form 8-K Starling Oncology, Inc. For: Aug 20

Fri, 21 Aug 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20260821/26962534.html

Form 8-K Starling Oncology, Inc. For: Aug 20

Fri, 21 Aug 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20260821/26962534.html

Form 144 Starling Oncology, Inc. Filed by: Hively Brad

Fri, 21 Aug 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260821/26961897.html

Form 144 Starling Oncology, Inc. Filed by: Hively Brad

Fri, 21 Aug 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260821/26961897.html

Form 144 Starling Oncology, Inc. Filed by: Hively Brad

Fri, 21 Aug 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260821/26961897.html

Starling Oncology launches Nexus oncology technology platform

Mon, 17 Aug 2026 08:04:24 -0400

Starling Oncology Inc. (NASDAQ: STLN) announced the launch of Starling Nexus, a proprietary technology platform designed to consolidate clinical decision support and prior authorization workflows for oncology providers.

According to a company statement, the platform addresses fragmented prior authorization processes and compliance with National Comprehensive Cancer Network guidelines, which the company describes as persistent challenges in cancer care delivery.

Starling Nexus combines real-time clinical decision support, evidence-based treatment pathways, and digital authorization submissions into a single oncology-specific workflow. The platform is also designed to integrate ancillary services such as pharmacy and clinical trials over time.

"Utilization management should support rapid access to high-quality

Starling Oncology Launches Starling Nexus™, a Technology Platform Built to Optimize Oncology Provider Engagement and Accelerate High-Quality Care at Scale

Mon, 17 Aug 2026 08:00:00 -0400

Company’s proprietary platform brings clinical decision support and evidence-based pathways into one streamlined oncology workflow

CERRITOS, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Starling Oncology™ Inc. (NASDAQ: STLN), (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today announced the launch of Starling Oncology Nexus, a proprietary technology platform built to address one of cancer care’s persistent challenges: NCCN compliance by the medical community and a fragmented and administratively burdensome prior authorization process for providers.

Oncology treatment decisions are complex and time-sensitive for patients, yet prior authorization often depends on

Starling Oncology Launches Starling Nexus™, a Technology Platform Built to Optimize Oncology Provider Engagement and Accelerate High-Quality Care at Scale

Mon, 17 Aug 2026 08:00:00 -0400

Company’s proprietary platform brings clinical decision support and evidence-based pathways into one streamlined oncology workflow

Oncology treatment decisions are complex and time-sensitive for patients, yet prior authorization often depends on

Starling Oncology Launches Starling Nexus™, a Technology Platform Built to Optimize Oncology Provider Engagement and Accelerate High-Quality Care at Scale

Mon, 17 Aug 2026 08:00:00 -0400

Company’s proprietary platform brings clinical decision support and evidence-based pathways into one streamlined oncology workflow

Oncology treatment decisions are complex and time-sensitive for patients, yet prior authorization often depends on

Starling Oncology Launches Starling Nexus™, a Technology Platform Built to Optimize Oncology Provider Engagement and Accelerate High-Quality Care at Scale

Mon, 17 Aug 2026 08:00:00 -0400

Company’s proprietary platform brings clinical decision support and evidence-based pathways into one streamlined oncology workflow

Oncology treatment decisions are complex and time-sensitive for patients, yet prior authorization often depends on

Increasing unusual option volume: STLN REAL EWC DOCS OMF WWR HTZ ARDX

Mon, 10 Aug 2026 04:13:41 -0400

Increasing unusual option volume: STLN REAL EWC DOCS OMF WWR HTZ ARDX

Form 10-Q Starling Oncology, Inc. For: Jun 30

Thu, 06 Aug 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260806/26884895.html

Form 10-Q Starling Oncology, Inc. For: Jun 30

Thu, 06 Aug 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260806/26884895.html

Form 10-Q Starling Oncology, Inc. For: Jun 30

Thu, 06 Aug 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260806/26884895.html

Form 8-K Starling Oncology, Inc. For: Aug 06

Thu, 06 Aug 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260806/26884805.html

Form 8-K Starling Oncology, Inc. For: Aug 06

Thu, 06 Aug 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260806/26884805.html

Form 8-K Starling Oncology, Inc. For: Aug 06

Thu, 06 Aug 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260806/26884805.html

Starling Oncology Reports Second Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance

Thu, 06 Aug 2026 16:14:00 -0400

CERRITOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its quarter ended June 30, 2026 and updated it's full-year 2026 guidance.

Recent Operational Highlights

Specialty Pharmacy had record Part D fills driving Specialty Pharmacy revenue up 58% in the quarter as compared to prior year same quarter, driven by continued strength in prescription fill volumes as we bring new capitated lives onto the platform, along with the